Heatwurx (PCSA) Stock Price, News & Analysis

Company Overview

Heatwurx was a pavement-maintenance technology company focused on infrared solutions for repairing asphalt. Its technology was designed to heat and soften existing pavement so damaged areas could be reworked and restored, potentially reducing the need to remove and replace asphalt.

The company’s product offerings included infrared asphalt-repair equipment and related materials intended for applications such as pothole repair, utility cuts, seams, and other localized pavement damage. Heatwurx marketed its solutions primarily to road-maintenance contractors, municipalities, and other organizations responsible for maintaining paved surfaces.

Public information about Heatwurx’s geographic coverage and leadership is limited. The company is also associated with a historical corporate transition: the public entity formerly connected with Heatwurx later changed its business focus and became Processa Pharmaceuticals, Inc., which trades on the Nasdaq under the symbol PCSA. Accordingly, current information associated with PCSA may not describe Heatwurx’s former asphalt-repair operations.

Key Stats

• Today's Range: $1.87 to $1.97
• 50-Day Range: $1.84 to $3.05
• 52-Week Range: $1.67 to $14.24
• Volume: 4,740 shs
• Average Volume: 24,736 shs
• Market Capitalization: $5.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Heatwurx Stock Analysis - MarketRank™

Heatwurx scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Heatwurx has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Heatwurx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Heatwurx has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.35% of the float of Heatwurx has been sold short.

Short Interest Ratio / Days to Cover

Heatwurx has a short interest ratio ("days to cover") of 1.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Heatwurx has recently decreased by 46.60%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Heatwurx does not currently pay a dividend.

Dividend Growth

Heatwurx does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Heatwurx in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $16,926.00 in company stock, which represents 0.3199% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Heatwurx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $16,926.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

3.50% of the stock of Heatwurx is held by insiders.

Percentage Held by Institutions

91.93% of the stock of Heatwurx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PCSA
• CIK: 1533743
• Web: www.processapharmaceuticals.com
• Phone: (443) 776-3133
• Fax: 443-288-4420
• Employees: 12
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): ($4.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -394.25%
• Return on Assets: -244.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.87
• Quick Ratio: 0.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.46 per share
• Price / Book: 0.78

Miscellaneous

• Outstanding Shares: 2,770,000
• Free Float: 2,671,000
• Market Cap: $5.29 million
• Optionable: Not Optionable
• Beta: 0.96